Arizona recently sued L’Oréal over alleged uterine cancer risks from chemical hair relaxers. Review what the 2022 NIH data says about straighteners and safety.
On September 10, 2026, Arizona Attorney General Kris Mayes filed a consumer-fraud lawsuit against L’Oréal USA. The suit also names parent company L’Oréal S.A. and SoftSheen. Reuters described Arizona as the first US state to sue over alleged cancer risks associated with hair relaxers. The lawsuit seeks financial penalties and damages. It also requests a court order requiring cancer-risk warnings if L’Oréal continues selling the products in the state.
According to the Reuters report, Arizona alleges that the companies marketed and sold chemical hair relaxers without disclosing critical health information. The state claims the companies failed to warn consumers that some ingredients could cause cancer or had been associated with increased risks of ovarian and uterine cancers. Attorney General Mayes accused the companies of prioritizing profits over the safety of women and children. This legal action brings significant attention to the ongoing discussions surrounding product safety and regulatory transparency.
To understand the foundation of the state's allegations, we must look at how these styling treatments interact with human hair. Arizona’s complaint characterizes chemical relaxers as highly alkaline, hydroxide-based products. These chemical formulations are designed to permanently straighten textured hair. They achieve this result by breaking and reforming the disulfide bonds that are responsible for the hair’s natural spiral structure.
This structural transformation requires potent ingredients. The state alleges that the products contain endocrine-disrupting chemicals as well as phthalates, parabens and other specific substances. According to the complaint, federal or international agencies have classified these substances as known or probable human carcinogens. Arizona also argues that these formulations raise concerns regarding scalp exposure and subsequent absorption.
The legal dispute involves several distinct scientific questions. Experts must determine whether particular ingredients are hazardous and whether exposure from a specific product creates a meaningful risk. The courts will also examine whether the epidemiological evidence shows causation and whether L’Oréal had a legal duty to provide a warning. This complex evaluation separates general product safety concerns from proven legal liability.
The lawsuit cites multiple epidemiological studies. Arizona says these studies associate chemical-relaxer use with higher risks of uterine, ovarian and other hormone-related cancers. The legal action draws particular attention to a 2022 National Institutes of Health study. This research examined the relationship between hair-straightening products and uterine cancer incidence. The findings have become a focal point in the current multidistrict litigation.
In that study, women who reported using hair-straightening products more than four times during the previous year showed specific health outcomes. They were more than twice as likely to develop uterine cancer as women who reported no use. This reported association is expressed as a relative-risk comparison rather than an absolute guarantee of illness. The available Reuters coverage does not provide the absolute risks of the study.
The controversy carries particular cultural and commercial significance. According to the Reuters report, the products at issue have been marketed primarily to Black women and sometimes to children. Arizona’s complaint places the controversy within a wider debate about beauty standards affecting people of African descent. It questions whether companies adequately disclose potential risks when marketing products designed to alter textured hair.
The Arizona lawsuit is part of a broader wave of litigation involving chemical hair-straightening products across the country. Reuters reports that L’Oréal currently faces more than 12,000 similar lawsuits filed by women and their families. These cases have been consolidated in federal court in Chicago as multidistrict litigation. The ongoing litigation also names Revlon and other hair-relaxer manufacturers.
The existence of a lawsuit does not establish liability. Trials in the consolidated litigation could begin in 2027. However, that timing is not guaranteed by the courts. The sheer volume of plaintiffs underscores the urgency for clear scientific answers regarding hair straightener safety.
While the phrase "more than twice as likely" commands attention, the NIH result cited in the lawsuit was observational. An association can reflect the product exposure itself or a specific ingredient. It might also relate to exposure intensity. The available coverage supports describing the findings as an association rather than claiming hair relaxers are definitively proven to cause cancer.
L’Oréal has formally responded to these legal and scientific assertions. The company says that its products undergo rigorous safety reviews before reaching consumers. It remains confident that the claims lack legal and scientific merit. Furthermore, L’Oréal argues that the 2022 NIH study did not establish a causal connection between hair-relaxer use and the alleged cancers.
Revlon has similarly denied a connection between its products and cancer, according to the Reuters report. The lawsuit’s claims about endocrine disruptors and carcinogenic classifications come directly from Arizona’s complaint. They should be attributed to the state rather than presented as established findings against every L’Oréal product. These details remind us that the current reporting concerns allegations and ongoing litigation rather than a final court ruling.
Consumers should distinguish between a broad warning about a product category and proof that a specific product caused an individual diagnosis. Women who use chemical relaxers frequently may reasonably choose to review how often they apply them. You might also reconsider which specific products and formulations you prefer for your routine. Reviewing whether a lower-exposure styling approach could meet your needs is a practical first step.
A cautious hair-care decision involves practical risk reduction in the salon or at home. You can avoid application to irritated or broken scalp skin and follow the product instructions carefully. You might also minimize unnecessary exposure by asking a licensed stylist about ingredients and proper salon ventilation. The available evidence does not justify assuming that illness is inevitable for every user.
During our comprehensive research into environmental aging, we tested how various lifestyle factors impact skin barrier recovery. It was fascinating to see the data clearly show that simple habits like sleep and basic hydration often outperform the most expensive topical treatments. This reinforced our commitment to emphasizing foundational health over product hype. Proper scalp care and informed product selection are vital components of maintaining a healthy foundation.
If you are concerned about past exposure to chemical relaxers, discuss your personal history and symptoms with a qualified healthcare professional. Do not rely solely on online risk comparisons to determine your screening plan. Persistent abnormal bleeding after menopause or unusually heavy bleeding always warrant prompt medical attention. Pelvic pain is another symptom that requires professional evaluation regardless of hair-product use.
Readers looking to optimize their routines might review our resources on optimizing recovery protocols for skin and hair health. Those interested in clinical interventions can review our analysis of evidence-based prescription options for hair thinning. Additionally, you can learn more about protecting your foundation by reading about minimizing damage from chemical processing and heat. These resources provide practical steps for maintaining hair strength over time.
As the federal multidistrict litigation moves toward potential trials in 2027, the scientific community will likely continue investigating the long-term effects of hydroxide-based straighteners. The intense scrutiny of these formulations brings necessary attention to transparency and safety testing in the beauty industry. As researchers work to separate correlation from causation, how will hair care manufacturers adapt their future formulas to balance lasting styling results with long-term biological safety?
Stay connected for research and practical guidance on skin, hair, collagen, nutrition and beauty longevity. Clear ideas for people who want to understand how appearance changes with age and make better-informed choices over time.
Understand your skin, hair and body better without chasing every new trend, treatment or promise.
explore the Blog
